THC plus CBD reduced MS-like symptoms in mice by reshaping gut bacteria | Research

The takeaway

A THC+CBD combination attenuated MS-like paralysis in mice, and fecal transplant experiments confirmed the effect was partly driven by cannabinoid-induced changes in gut bacteria.

MS researchers, gut-brain axis scientists, and anyone interested in how cannabinoids interact with the microbiome.

Gut bacteria drove the effect

What the researchers found

THC+CBD treatment reduced a mucin-degrading gut bacterium (Akkermansia muciniphila) that was elevated in EAE mice, lowered brain LPS levels, and increased beneficial short-chain fatty acids. Fecal transplants from treated mice to untreated mice confirmed that gut microbiome changes played a critical role in the therapeutic effect.

Why it matters

The gut-brain axis is increasingly recognized as a factor in neurological diseases. This study provides direct evidence that cannabinoids can reshape the gut microbiome in ways that reduce neuroinflammation, adding a new dimension to how cannabis-based medicines might work in MS.

The numbers in context

THC+CBD significantly reduced Akkermansia muciniphila abundance. Brain LPS levels were elevated in EAE mice and reversed by treatment. Short-chain fatty acids (butyric, isovaleric, and valeric acids) were significantly higher in treated mice compared to disease controls.

How the study worked

Mouse model of MS (EAE) treated with THC+CBD combination. Used 16S rRNA sequencing to analyze gut microbiome composition. Fecal material transfer experiments tested whether microbiome changes were causally involved. In silico metabolomics analyzed bacterial metabolic pathways.

What this study cannot tell us

Mouse gut microbiome composition differs from humans. EAE is an imperfect model of human MS. The fecal transplant experiments confirm causality in mice but not in humans. Specific bacterial species involved may differ across species.

How to read the evidence

Rated preliminary because this is a mouse study. The fecal transplant experiments strengthen the causal claim, but human translation remains untested.

When this study was published

Published in 2019. Gut-brain axis research in MS has continued to expand since.

The bigger picture

This study connects two hot research areas: the gut microbiome and cannabinoid therapeutics. If cannabinoids improve neuroinflammation partly by fixing gut dysbiosis, it could change how we think about dosing, timing, and monitoring cannabis-based MS treatments.

Questions still open

Do human MS patients on cannabinoid therapy show similar gut microbiome shifts? Could probiotic interventions complement cannabinoid treatment? Is the gut microbiome effect specific to THC+CBD or would other cannabinoids work similarly?

Common questions

How did gut bacteria relate to MS symptoms?

EAE mice had elevated levels of mucin-degrading bacteria and higher brain LPS (a bacterial toxin). THC+CBD treatment reversed both changes, and transferring feces from treated mice to untreated mice reproduced the benefit.

What are short-chain fatty acids?

They are metabolic byproducts of gut bacteria that have anti-inflammatory effects. THC+CBD-treated mice had significantly higher levels of butyric, isovaleric, and valeric acids.

Does this mean probiotics could help MS?

The study raises that possibility but did not test it directly. It showed that cannabinoid-driven microbiome changes contributed to reduced neuroinflammation.

Read the original research

Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.

Brain, behavior, and immunity, 82, 25-35

View on PubMed ↗Publisher’s paper ↗

Citation

Al-Ghezi, Zinah Zamil; Busbee, Philip Brandon; Alghetaa, Hasan; Nagarkatti, Prakash S; Nagarkatti, Mitzi. (2019). Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.. Brain, behavior, and immunity, 82, 25-35. https://doi.org/10.1016/j.bbi.2019.07.028